5 Value Stocks In The Communication Services Sector

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the…

What is a Value Stock?

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga Insights has compiled a list of value stocks in the communication services sector that may be worth watching:

  1. Gray Television (NYSE:GTN) – P/E: 2.26
  2. Liberty Broadband (NASDAQ:LBRDA) – P/E: 9.63
  3. Liberty SiriusXM Gr (NASDAQ:LSXMK) – P/E: 7.5
  4. Jiayin Gr (NASDAQ:JFIN) – P/E: 1.26
  5. Lizhi (NASDAQ:LIZI) – P/E: 4.18

Gray Television’s earnings per share for Q4 sits at $1.88, whereas in Q3, they were at 1.03. Its most recent dividend yield is at 2.51%, which has increased by 0.14% from 2.37% in the previous quarter.

Liberty Broadband’s earnings per share for Q4 sits at $1.26, whereas in Q3, they were at 2.05. This quarter, Liberty SiriusXM Gr experienced an increase in earnings per share, which was $0.06 in Q3 and is now $1.54. Jiayin Gr’s earnings per share for Q3 sits at $0.64, whereas in Q2, they were at 0.72. Lizhi looks to be undervalued. It possesses an EPS of $0.07, which has not changed since last quarter (Q2).

These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

Total
0
Shares
Related Posts
Read More

Spire: Q2 Earnings Insights

  Spire (NYSE:SR) reported its Q2 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Spire beat estimated earnings by 10.32%, reporting an EPS of $3.42 versus an estimate of $3.1.

SR

Read More

Immutep Announced Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the Independent Data Monitoring Committee (IDMC) for the randomised, controlled Phase IIb TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modificatio

IMMP